Spyre Therapeutics, Inc. (SYRE) Tops Q3 EPS by 62c

Spyre Therapeutics, Inc. (NASDAQ: SYRE) reported Q3 EPS of ($0.15), $0.62 better than the analyst estimate of ($0.77).

For earnings history and earnings-related data on Spyre Therapeutics, Inc. (SYRE) click here.

You May Also Be Interested In

• Intuit (INTU) Misses Q4 EPS; Offers FY27 Guidance
• Ryman Hospitality closes $700M notes offering for Orlando acquisition
• Strattec Security Corp (STRT) Tops Q4 EPS by 94c